Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience. Issue 6 (31st January 2022)

• Record Type: Journal Article
• Authors: Grova, Mauro; Crispino, Federica; Maida, Marcello; Renna, Sara; Mannino, Mariella; Casà, Angelo; Rizzuto, Giulia; Macaluso, Fabio Salvatore; Orlando, Ambrogio
• Is Part Of: European journal of gastroenterology & hepatology. Volume 34:Issue 6(2022)
• Page Start: 607
• Page End: 612
• Publication Date: 2022-01-31
• Subjects: ferric carboxymaltose -- inflammatory bowel disease -- intravenous iron -- iron deficiency anemia; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000002348
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Background: We evaluated an on-demand ferric carboxymaltose (FCM) infusion strategy in inflammatory bowel disease (IBD) patients with iron deficiency anemia (IDA). Aims: The primary outcome was the response rate to single or multiple FCM infusions after 12 months. Secondary outcomes were the response rate to a single FCM infusion after 3 months and the FCM safety profile. Methods: We retrospectively included 185 IBD patients who received at least one FCM infusion of 500 mg, between 2015 and 2018. FCM was administered to patients with Hb ≤10 g/dL and hypoferritinemia and repeated according to the physician's assessment. Complete response (CR) was defined as Hb ≥12 g/dL (≥13 g/dL for men) or Hb increase ≥2 g/dL. Partial response (PR) was defined as an Hb increase between 1 and 2 g/dL. A univariate analysis was performed at 3 and 12 months. Results: After 12 months, the response rate was 75.1% (CR, 48.6%; PR, 26.4%; mean number of FCM infusions, 1.7 ± 1.1). In total 169/185 patients received a single FCM infusion during the first 3 months and 79.2% achieved response (CR, 56.8%; PR, 22.4%). At univariate analysis, no variable was associated with response. No adverse events were reported. Conclusions: An on-demand strategy was effective and well-tolerated in treating IDA in IBD patients.